Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (181-190 of 361) with videos related to

Pageof 37
Sort By:
Journal of the American College of Cardiology|January 28, 2022
Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart FailureAlvin Chandra, Hicham Skali, Brian Claggett, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JACC. Heart Failure|September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF AnalysisLuis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|October 18, 2018
Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapyMaja Cikes, Sergio Sanchez-Martinez, Brian Claggett, et al.
European Journal of Heart Failure|June 27, 2023
Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysisDaniel Modin, Mats Christian Højbjerg Lassen, Brian Claggett, et al.
Journal of the American Heart Association|August 24, 2022
Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC StudyJenine E John, Brian Claggett, Hicham Skali, et al.
European Heart Journal|September 17, 2015
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D Solomon, Brian Claggett, Eldrin F Lewis, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
American Heart Journal|August 25, 2015
Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitusEldrin F Lewis, Brian Claggett, Patrick S Parfrey, et al.
Pageof 37

Showing results (181-190 of 361) with videos related to

Sort By:
Pageof 37
Journal of the American College of Cardiology|January 28, 2022
Race- and Gender-Based Differences in Cardiac Structure and Function and Risk of Heart FailureAlvin Chandra, Hicham Skali, Brian Claggett, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Circulation. Heart Failure|April 13, 2018
Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)Orly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
JACC. Heart Failure|September 13, 2020
Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF AnalysisLuis E Rohde, Neal A Chatterjee, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|October 18, 2018
Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapyMaja Cikes, Sergio Sanchez-Martinez, Brian Claggett, et al.
European Journal of Heart Failure|June 27, 2023
Influenza vaccination and cardiovascular events in patients with ischaemic heart disease and heart failure: A meta-analysisDaniel Modin, Mats Christian Højbjerg Lassen, Brian Claggett, et al.
Journal of the American Heart Association|August 24, 2022
Coronary Artery Disease and Heart Failure With Preserved Ejection Fraction: The ARIC StudyJenine E John, Brian Claggett, Hicham Skali, et al.
European Heart Journal|September 17, 2015
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D Solomon, Brian Claggett, Eldrin F Lewis, et al.
European Journal of Heart Failure|February 13, 2018
Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrumLars H Lund, Brian Claggett, Jiankang Liu, et al.
American Heart Journal|August 25, 2015
Race and ethnicity influences on cardiovascular and renal events in patients with diabetes mellitusEldrin F Lewis, Brian Claggett, Patrick S Parfrey, et al.
Pageof 37